FDA 批准扩大默克公司 Keytruda 组合治疗宫颈癌的使用范围。 FDA approves expanded use of Merck's Keytruda combo for cervical cancer.

FDA 已批准默克公司的免疫疗法 Keytruda 与放化疗联合用于治疗既往未接受过手术、放疗或全身治疗的新诊断晚期宫颈癌患者。 The FDA has approved Merck's immunotherapy Keytruda in combination with chemoradiotherapy for treating newly diagnosed advanced cervical cancer patients who have not received previous surgery, radiation, or systemic therapy. 这使得 Keytruda 联合放化疗成为美国批准用于新诊断宫颈癌患者的第一个基于抗 PD-1 的免疫治疗组合。 This makes Keytruda plus chemoradiotherapy the first anti-PD-1-based immunotherapy combination approved in the US for newly diagnosed cervical cancer patients.